Cytokinetics, Incorporated (NASDAQ:CYTK) Pressured Under Trend Lines


Currently Cytokinetics, Incorporated (NASDAQ:CYTK)'s shares owned by insiders are 0.40%, whereas shares owned by institutional owners are 74.90%. The recent price momentum makes it one stock to watch in recent days. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. On October 27 HC Wainwright held the stock rating at "Buy" with a current price target of $26.00. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. Of those transactions, there were 358,750 shares of CYTK bought and 287,299 shares sold. Earnings surprises can have a huge impact on a company's stock price. Fady Ibraham Malik, EVP Research & Development let go of $97,955 worth of shares at an average price of $13.38 on Wednesday the 1st. We see here that Cytokinetics, Incorporated (NASDAQ:CYTK) is -35.13% away from the 20-Day Simple Moving Average.

This company shares (EVR) so far managed to recover 32.46% since collapsing to its 52-week low. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics, Inc. (NASDAQ:CYTK) was the target of a significant growth in short interest in the month of April. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.04.

Analysts are also projecting an Average Revenue Estimate for Cytokinetics, Incorporated as $6890 in the Current Quarter.

Cytokinetics, Incorporated (NASDAQ:CYTK) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Week Herald and is the property of of Week Herald. ValuEngine upgraded shares of Cytokinetics, from a sell rating to a hold rating in a report on Friday, September 1st. Finally, Cantor Fitzgerald reissued a "buy" rating and set a $21.00 price target on shares of Cytokinetics, in a research report on Monday, September 18th. Also, Director Santo J. Costa sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, August 29th.

Hedge funds have recently added to or reduced their stakes in the company.

"While we are deeply disappointed by the results of VITALITY-ALS, we remain committed to people with ALS who are fighting this devastating disease and who need new therapies to slow the decline of respiratory function and muscle strength that are key hallmarks of disease progression", said Robert I. Blum, Cytokinetics' president and CEO. Municipal Employees Retirement System of MI bought a new stake in shares of Cytokinetics, in the 2nd quarter valued at approximately $132,000. Pinnacle Associates Ltd. purchased a new position in shares of Cytokinetics, during the 3rd quarter valued at approximately $14,628,000. Insiders have sold 178,223 shares of company stock worth $2,639,239 over the last 90 days. Insiders own 7.20% of the company's stock.

As regular trading ended, Cytokinetics, Incorporated (CYTK) stock brought in a -$0.7 drop to $11.1. Cytokinetics is collaborating with Amgen develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company's stock valued at $9,271,000 after purchasing an additional 431,457 shares in the last quarter.